Abstract：
:Murine erythroleukemia (MEL) cells undergo erythroid differentiation in vitro when treated with hexamethylene bisacetamide (HMBA). To identify genes involved in the commitment of MEL cells to differentiate, we screened a cDNA library constructed from HMBA-induced cells by differential hybridization and isolated GTPase Ran as a down-regulated gene. We observed that Ran was expressed in a biphasic mode. Following a decrease in mRNA level during the initial hours of induction, Ran re-expressed at 24-48 h, and gradually declined again. To investigate the role of Ran during MEL differentiation we constructed MEL transfectants capable to express or block Ran mRNA production constitutively. No effects were observed on cell growth and proliferation. Blockage of Ran, however, interfered with MEL cell differentiation resulting in a decrease of cell survival in the committed population.
journal_name
Leuk Resjournal_title
Leukemia researchauthors
Vanegas N,García-Sacristán A,López-Fernández LA,Párraga M,del Mazo J,Hernández P,Schvartzman JB,Krimer DBdoi
10.1016/s0145-2126(02)00231-xkeywords:
subject
Has Abstractpub_date
2003-07-01 00:00:00pages
607-15issue
7eissn
0145-2126issn
1873-5835pii
S014521260200231Xjournal_volume
27pub_type
杂志文章abstract：:We investigated protracted low-dose oral Clofarabine for the treatment of myelodysplastic syndromes (MDS). Adults with an International Prognostic Scoring System (IPSS) score of INT-1 or higher who had failed first line therapy were eligible. INT-1 patients had to be transfusion-dependent. We started with oral Clofara...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2015.05.004
更新日期：2015-08-01 00:00:00
abstract：:Clofarabine (CLO), a purine nucleoside analog with promising efficacy in acute myeloid leukemia (AML), inhibits the ribonucleotidereductase, p53R2. We have shown that p53R2 mRNA is up-regulated by decitabine (DEC), another drug with promising activity in AML. We developed a pharmacodynamic model to characterize the in...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2012.07.015
更新日期：2012-11-01 00:00:00
abstract：:A retrospective analysis of the relationship between the initial classification according to either FAB or WHO criteria, the presence of risk factors and the type of therapy including stem cell transplantation (SCT) on the survival was performed in a group of 106 patients with primary myelodysplastic syndrome (MDS) of...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2003.10.016
更新日期：2004-06-01 00:00:00
abstract：:Flow cytometry is commonly used to establish the diagnosis of chronic lymphocytic leukemia (CLL). A defined combination of antibodies discriminates between normal B cells and CLL cells (coexpression of CD5, CD19, and CD23). The receptor tyrosine-like orphan receptor one (ROR1) is an embryonic glycoprotein involved in ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2011.04.006
更新日期：2011-10-01 00:00:00
abstract：OBJECTIVE:Bortezomib-dexamethasone-thalidomide has been reported to be effective in newly-diagnosed multiple myeloma (MM) with an overall response rate of 92% and a CR rate of 18% (Alexanian et al, Hematology 2007;12(3):235-9), but this regimen has not been tested in the Chinese patients. We report here our results tes...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2009.04.006
更新日期：2009-12-01 00:00:00
abstract：:In a prospective study of 27 patients with acute myeloid leukaemia (AML) quality of life was studied using three different instruments, Life Ingredient Profile, Karnofsky Performance Scale and Vitagram. The course of the disease was followed during the induction period, remission, relapse and in the terminal phase. We...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(94)90028-0
更新日期：1994-04-01 00:00:00
abstract：:Dose reductions or interruptions may be required to manage treatment-associated adverse events among patients with myelodysplastic syndromes (MDS) treated with lenalidomide; such modifications are recommended to sustain therapy and maximize treatment duration. The aim of this retrospective case-control study was to de...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2017.10.005
更新日期：2017-12-01 00:00:00
abstract：:The biological progression of chronic myeloid leukaemia is often associated with secondary cytogenetic abnormalities but the molecular mechanisms underlying this progression are poorly understood. This study explores the association of c-myc gene amplification with the progression of chronic myeloid leukaemia in fourt...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/s0145-2126(98)00097-6
更新日期：1998-10-01 00:00:00
abstract：:Allogeneic stem cell transplantation is considered to be a curative treatment modality in patients with chronic myelogenous leukemia. However patients are at risk for relapse years after transplantation. Currently we present two patients who relapsed 16 and 24 years after allogeneic bone marrow transplantation, respec...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2009.03.010
更新日期：2009-09-01 00:00:00
abstract：:The genes for the CDK4/6-inhibitors p16INK4A/MTS1 and p15INK4B/MTS2 are frequently deleted in hematological malignancies. A new member of this family of CDK4/6 inhibitors is p18. In order to assess p18 growth-suppressor gene alterations in hematological neoplasms, we investigated 31 lymphoma and leukemia cell lines by...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(95)00137-9
更新日期：1996-02-01 00:00:00
abstract：BACKGROUND:The use of intensive pediatric protocols for the treatment of ALL is being extended to older adults. AIM OF THE STUDY:Analysis of the efficacy and toxicity results of pediatric DFCP vs. classic Hyper-CVAD protocol for the treatment of patients with ALL < 50 Y. PATIENTS AND METHODS:A retrospective single ce...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2017.06.010
更新日期：2017-09-01 00:00:00
abstract：:Infant leukemia cells with 46XY,t(11; 17)(q23; p13) karyotype and a hybrid pre B myeloid phenotype (HLA-DR, (Ia), B4 and My7-positive and CALLA and T11-negative) and immunoglobulin heavy chain gene rearrangement were maintained in long-term culture for over 10 months. The in-vitro survival and growth of the leukemia c...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(86)90253-5
更新日期：1986-01-01 00:00:00
abstract：:Aggressive chemotherapy of myelodysplastic syndromes is rarely feasible because these disorders predominantly occur in elderly patients who often have concurrent illnesses. Alternative treatment modalities must therefore be evaluated. This review summarizes the results that have been obtained with low-dose chemotherap...
journal_title：Leukemia research
pub_type： 杂志文章,评审
doi：10.1016/0145-2126(92)90058-f
更新日期：1992-01-01 00:00:00
abstract：:Imatinib is a tyrosine kinase inhibitor and is now used regularly in chronic myeloid leukaemia therapy in chronic phase with great success. This drug due its very nature of action is suspected to be teratogenic hence the patients are counseled not to get pregnant while on this drug. However in world literature few nor...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2008.03.007
更新日期：2008-10-01 00:00:00
abstract：:A patient with myelodysplastic syndromes (MDS) developed eosinophilia during treatment with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). To study the mechanism of this eosinophilia, we investigated the proliferation of eosinophil colony-forming units (CFU-Eo) in nine patients and four...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(95)00083-6
更新日期：1995-12-01 00:00:00
abstract：:240 patients with MDS studied cytogenetically at diagnosis between 1981 and 1990 were followed until death or until April 1992 to evaluate the prognostic significance of FAB classification, age and karyotype. 61 patients (25.4%) subsequently transformed into AML and 176 (73.3%) died during the follow-up period. Patien...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(94)00131-s
更新日期：1995-05-01 00:00:00
abstract：:Microtubular reorganisation contributing to apoptotic morphology occurs in normal and neoplastic cells undergoing apoptosis induced by cytotoxic drugs [1-3]. The aim of this study was to correlate the changes in the microtubules (MTs) with behavior of the centrosome in apoptotic cells, and to see whether post-translat...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/s0145-2126(97)00038-6
更新日期：1997-06-01 00:00:00
abstract：:Mutations in Janus kinase 2 (JAK2) are implicated in the pathogenesis of Philadelphia-chromosome negative myeloproliferative neoplasms, including primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Gandotinib (LY2784544), a potent inhibitor of JAK2 activity, shows increased potency for the JAK2V61...
journal_title：Leukemia research
pub_type： 杂志文章,多中心研究
doi：10.1016/j.leukres.2017.08.010
更新日期：2017-10-01 00:00:00
abstract：:The amplified myeloma centrosome has been identified as a therapeutic target. The present study explored the expression and prognostic significance of the centrosome-associated protein PLK1 in myeloma and the effect of BI 2536, a potent and selective inhibitor of PLK1, on myeloma cells. High plasma cell expression of ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2011.07.016
更新日期：2011-12-01 00:00:00
abstract：:Acute myeloid leukemia is an aggressive disease that arises from clonal expansion of malignant hematopoietic precursor cells of the bone marrow. Deletions on the long arm of chromosome 9 (del(9q)) are observed in 2% of acute myeloid leukemia patients. Our deletion analysis in a cohort of 31 del(9q) acute myeloid leuke...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2018.11.007
更新日期：2019-01-01 00:00:00
abstract：:The aims were to investigate the feasibility of imatinib mesylate (IM) discontinuation in chronic myeloid leukemia patients who were initially treated with IM and achieved complete molecular response (CMR). Fourteen patients were included. Ten were relapsed within 9.5 months after discontinuation of IM. All 7 patients...
journal_title：Leukemia research
pub_type： 杂志文章,多中心研究
doi：10.1016/j.leukres.2012.02.011
更新日期：2012-06-01 00:00:00
abstract：:Using the human erythroleukaemic cell line K562 cl.6 and its daunorubicin-resistant subline K/DAU600, and the human T-lymphoblastic leukaemic cell line CCRF-CEM and its vinblastine-resistant subline CEM/VLB100, we have shown that the drug-resistant cell lines were more sensitive to cytotoxicity induced by tumour necro...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(94)00149-5
更新日期：1995-03-01 00:00:00
abstract：:There is resurgent interest in glucocorticoids (GCs) in the treatment of poor prognosis chronic lymphocytic leukemia (CLL). Little is known however on how GCs induce apoptosis in CLL. Methylprednisolone (MP) induces apoptosis in ZAP-70 positive CLL more readily than in ZAP-70 negative CLL, which is in contrast to the ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2009.02.022
更新日期：2009-10-01 00:00:00
abstract：:The effect of VM-26, a topoisomerase II targeting drug, on IW32 murine erythroleukemia cells was investigated. The VM-26 induced IW32 cells to differentiate at a non-toxic but cytostatic concentration (0.01 microgram/ml). More than 40% of the cells were induced to synthesize hemoglobin, and cells were arrested in G2/M...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(95)00144-1
更新日期：1996-03-01 00:00:00
abstract：:The aberrant changes of tumor suppressor genes (TSGs) are now recognized as an important mechanism contributing to the development of acute myeloid leukemia (AML). CCAAT/enhancer binding protein zeta (C/EBPζ), a candidate TSG, has been found to be involved in cancers including AML. We detected the methylation status o...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2010.10.031
更新日期：2011-07-01 00:00:00
abstract：:We analyzed surface antigens, multidrug resistance (MDR) parameters (PGP, MRP, LRP), tissue infiltration parameters (CD18, CD44, VCAM, MMP2), receptors for colony stimulating factors (G-CSFr, GM-CSFr) and cell cycle parameters (Ki-67, topoisomerase IIalpha) in 86 patients with acute lymphoblastic leukemia (ALL). LRP, ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/s0145-2126(03)00026-2
更新日期：2003-10-01 00:00:00
abstract：:Although biological and clinical features differ between B-lineage acute lymphoblastic leukemia (ALL) and T-lineage ALL (T-ALL), there have been few reports that focused on the prognosis for T-ALL in adults, primarily due to its rarity. Here, we studied the long-term outcomes and prognostic factors specific for adult ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2006.08.004
更新日期：2007-07-01 00:00:00
abstract：:ABCG2 encodes a transporter protein that is associated with multidrug-resistant phenotypes in many cancers, including acute myeloid leukemia (AML); high levels of expression are generally associated with a poor prognosis. To better understand how expression of ABCG2 is controlled in pediatric AML, we performed a detai...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2011.05.004
更新日期：2011-10-01 00:00:00
abstract：:Serial samples of peripheral blood were obtained from 75 children with acute lymphoblastic leukemia in remission. An immunofluorescence assay was used to quantitate TdT-containing (terminal deoxynucleotidyl transferase-containing) cells in the mononuclear leukocyte fraction of these specimens. Nine relapses in 8 patie...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(87)90089-0
更新日期：1987-01-01 00:00:00
abstract：:In this study we explored the effects of bryostatin-5 on the clonogenic response of normal bone marrow mononuclear (BM) cells and HL60 myeloid leukemia cells. Leukemic HL60 colony formation was strongly inhibited by bryostatin-5 depending on dose and schedule. An inhibitory effect on HL60 colony formation was readily ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(94)00118-t
更新日期：1995-01-01 00:00:00
